Stephen Kraus, a partner in the Cambridge, Mass. office, has worked with Bessemer since 2004 and focuses on the healthcare sector.
Currently, he focuses his new deal activity on early and growth stage opportunities in healthcare IT and healthcare services. He currently sits on the boards of Liazon, Health Essentials, DocuTAP, Ovascience, Verastem, Allena Pharmaceuticals and Alcresta and is actively involved in BVP's investments in Acceleron and Proteon.
Steve has been actively involved in Bessemer’s investments in Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ: AFFY); Aveo (NASDAQ: AVEO); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec, Verastem (NASDAQ: VSTM), and Restore Medical (NASDAQ: REST), acquired by Medtronic.
Prior to joining Bessemer, Steve was a director at the Ironwood Equity Fund, a growth-stage, private-equity firm, and a management consultant at Bain & Co. In 2002, he served as speechwriter and operations director for the Democratic nominee for governor of Massachusetts
Steve graduated summa cum laude with a B.A. from Yale University and earned his MBA from Harvard, where he was a Baker Scholar.
He serves on the boards of the New England Venture Capital Association (NEVCA), the Achievement Network, and Interise. Steve was recently recognized by Forbes Magazine as one of the top life science investors if 2013.
Steve regularly blogs with BVP's Ambar Bhattacharyya at HCVC's(two healthcare investors' musings on work and life).
Board & Advisor Roles (8)Update
|Jul, 2016||Docent Health||$15M / Series A (Lead)||Bessemer Venture Partners|
|Jun, 2016||Alcresta||$49.39M / Venture (Lead)||Bessemer Venture Partners|
|Apr, 2016||Bright Health||$80M / Series A (Lead)||Bessemer Venture Partners|
|Dec, 2014||Allena Pharmaceuticals||$25M / Series B||Bessemer Venture Partners|
|Jul, 2013||Alcresta||$10M / Series B (Lead)||Bessemer Venture Partners|
|Apr, 2012||Liazon||$18.2M / Series D||Bessemer Venture Partners|
|Apr, 2012||Alcresta||$10M / Series A (Lead)||Bessemer Venture Partners|
|Nov, 2011||Allena Pharmaceuticals||$15M / Series A (Lead)||Bessemer Venture Partners|
|Apr 6, 2016||PE HUB - Bright Health raises $80 mln; Series A round led by Bessemer and NEA|
|Apr 6, 2016||Business Wire - Bright Health Raises $80 Million in Series A Funding Led by Bessemer Venture Partners and NEA|
|Aug 17, 2015||Venture Beat - This year’s digital health IPOs have put the market in the mood for more|
|Oct 15, 2014||Xconomy - Welltok Raises $25M More, Takes Aim at $2.7T Healthcare Industry|
|Oct 15, 2014||PRNewswire All - Welltok Raises $25 Million to Optimize Consumers' Health|
|May 20, 2013||Venture Beat - Attention digital health startups: VCs say now is a 'great' time to raise money|
|Oct 12, 2011||Xconomy - OvaScience Uses Stem Cells to Revive Fertility|
|Jan 11, 2011||VCCircle - Bessemer Promotes Two India VPs To Partners|